• Home
  • PR

PR

News

게시물 상세
OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress
Date : 2022-03-22     View : 549

 

 

OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

 

 

SUWON, South Korea., Mar. 16, 2022 -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that Behfar Ardehali, Ph.D., Senior Scientist of the Company, presented at the 7th Annual OPT Congress Oligonucleotide & Precision Therapeutics. The OPT Congress is being held both in-person and virtually March 15-16, 2022. At the congress, Dr. Ardehali discussed the potential utility of GalNAc-asiRNA platform for treatment of liver diseases and presented the Company’s latest advancements in liver programs, including Nonalcoholic steatohepatitis (NASH) and HBV.

 

Details for the presentation are below:

 

Presentation: Development of a GalNAc-asiRNA Platform for Treatment of Liver Disorders

Date & Time: Tuesday, March 15, 2022 at 11:00 AM EDT

Location: Revere Hotel Boston Common, USA

Event Link: https://www.optcongress.com

 

 

###

 

Prev OliX Pharmaceuticals to Participate in BIO-Europe Spring®
Next OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference